News & Updates

Show Multimedia Only

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026 by

A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026

Juvenile-onset mycosis fungoides progression not common, survival high: study

22 Aug 2026

Juvenile-onset mycosis fungoides (jMF) is usually diagnosed during its early stage and has an excellent prognosis, with overall survival (OS) of 99 percent at 5 years and 98 percent at 10 years, reveals a study.

Juvenile-onset mycosis fungoides progression not common, survival high: study

22 Aug 2026

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026 by

A study conducted by the Asia-Pacific Oncology Drug Development Consortium finds substantial variability in regulatory approval delays of pembrolizumab and trastuzumab deruxtecan (T-DXd) across 10 Asia-Pacific (APAC) territories, and a lack of consistent prioritization of high-incidence tumours, high clinical benefit scores or curative treatment intent.

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026

Tim-3 blockade controls tumour growth in metabolic liver cancer

17 Aug 2026

In patients with steatohepatitis-related hepatocellular carcinoma (HCC), Tim-3 plays a key role in regulating dendritic cell (DC) ferroptosis, with its expression predicting poor prognosis, suggests a study.

Tim-3 blockade controls tumour growth in metabolic liver cancer

17 Aug 2026

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026 by

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

13 Aug 2026 by

Neoadjuvant immune checkpoint inhibitor (ICI) therapy demonstrates notable activity in non-metastatic deficient mismatch repair/microsatellite instability-high (dMMR/MSI) colorectal cancer (CRC), with high response rates and favourable clinical outcomes, as shown in the ongoing ambispective international observational study AGEO-NEO-MSI.

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

13 Aug 2026

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

12 Aug 2026

In patients with familial adenomatous polyposis (FAP), treatment with encapsulated rapamycin is safe and appears to lower polyp burden, according to a phase II study.

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

12 Aug 2026

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

12 Aug 2026 by

Treatment with STRIDE*, with or without lenvatinib, plus TACE** significantly improves progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) in patients with embolization-eligible hepatocellular carcinoma (eeHCC) compared with TACE alone, according to the phase III EMERALD-3 trial presented at ESMO GI 2026.

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

12 Aug 2026

Add-on high-dose vitamin D3 of little benefit in mCRC

11 Aug 2026

Adding high-dose vitamin D3 to standard chemotherapy does not appear to improve outcomes in patients with previously untreated metastatic colorectal cancer (mCRC), as shown in a phase III trial.

Add-on high-dose vitamin D3 of little benefit in mCRC

11 Aug 2026

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026 by

Researchers from the Clinical Neuroscience Consortium (CNC), a collaborative platform jointly established by the University of Hong Kong (HKU) and Queen Mary Hospital in collaboration with the Hong Kong Genome Institute (HKGI), have achieved a major breakthrough in brain cancer research, uncovering thousands of previously unannotated isoforms and identifying potential targets for both precision therapeutics and personalized cancer vaccines.

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

Juvenile-onset mycosis fungoides progression not common, survival high: study

Juvenile-onset mycosis fungoides progression not common, survival high: study

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

Tim-3 blockade controls tumour growth in metabolic liver cancer

Tim-3 blockade controls tumour growth in metabolic liver cancer

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

Real-world data support neoadjuvant immunotherapy in dMMR/MSI CRC

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

Encapsulated rapamycin a promising chemopreventive agent in familial adenomatous polyposis

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

STRIDE-based regimen improves PFS, tumour responses in eeHCC patients

Add-on high-dose vitamin D3 of little benefit in mCRC

Add-on high-dose vitamin D3 of little benefit in mCRC

A leap forward towards more precise and individualized immunotherapy for glioblastoma

A leap forward towards more precise and individualized immunotherapy for glioblastoma